2020
CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS
Chavez C, Everson R, Orpilla J, Lee A, Khattab S, Antonios J, Salazar A, Cloughesy T, Liau L, Sun L, Hugo W, Prins R. CTIM-18. DENDRITIC CELL VACCINATION IN CONJUNCTION WITH ADJUVANT TLR-3 AGONIST ADMINISTRATION ENHANCES PRO-INFLAMMATORY IMMUNE RESPONSES AND IS ASSOCIATED WITH EXTENDED SURVIVAL IN MALIGNANT GLIOMA PATIENTS. Neuro-Oncology 2020, 22: ii36-ii37. PMCID: PMC7650313, DOI: 10.1093/neuonc/noaa215.152.Peer-Reviewed Original ResearchPatient's peripheral blood mononuclear cellsMalignant glioma patientsToll-like receptorsImmune responsePoly ICLCDendritic cellsClinical trialsTumor lysate-pulsed DCGlioma patientsTLR-3Lysate-pulsed DCPeripheral blood mononuclear cellsPhase II clinical trialTLR-7 agonistDendritic cell vaccinesPro-inflammatory immune responseWHO grade IIITLR-3 agonistIncreased expression of pro-inflammatory genesMGMT methylation statusBlood mononuclear cellsII clinical trialsExpression of pro-inflammatory genesPro-inflammatory responseExpression of pro-inflammatory factors
2018
ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION
Antonios J, Everson R, Soto H, Khattab S, Bethel J, Sun M, Mochizuki A, Lee A, Odesa S, Billingslea-Yoon E, Moughon D, Wang A, Cloughesy T, Prins R, Liau L. ATIM-39. IMPROVED SURVIVAL NOTED IN GLIOBLASTOMA PATIENTS TREATED WITH ADJUVANT TLR-3 AGONIST IN SETTING OF AUTOLOGOUS LYSATE-PULSED DC VACCINATION. Neuro-Oncology 2018, 20: vi10-vi10. PMCID: PMC6216157, DOI: 10.1093/neuonc/noy148.034.Peer-Reviewed Original ResearchToll-like receptorsMedian survivalDendritic cellsDC vaccinesGrade III or IV gliomaTumor lysate-pulsed DCGlioblastoma multiformePoly ICLCAutologous tumor lysateDC vaccine treatmentLysate-pulsed DCMGMT methylated tumorsMGMT unmethylated tumorsTLR-7 agonistPeripheral blood mononuclear cellsGrade III tumorsTLR-3 agonistIncreased overall survivalGrade IV tumorsBlood mononuclear cellsModulate immune responsesIII tumorsIV tumorsMethylated tumorsOverall survival